These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33647591)

  • 1. Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).
    Pérez-Miralles F; Prefasi D; García-Merino A; Ara JR; Izquierdo G; Meca-Lallana V; Gascón-Giménez F; Martínez-Ginés ML; Ramió-Torrentà L; Costa-Frossard L; Fernández Ó; Moreno-García S; Medrano N; Maurino J; Casanova B
    Mult Scler Relat Disord; 2021 May; 50():102860. PubMed ID: 33647591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.
    Pérez-Miralles FC; Prefasi D; García-Merino A; Ara JR; Izquierdo G; Meca-Lallana V; Gascón-Giménez F; Martínez-Ginés ML; Ramió-Torrentà L; Costa-Frossard L; Fernández Ó; Moreno-García S; Maurino J; Carreres-Polo J; Casanova B
    Brain Behav; 2021 Apr; 11(4):e02044. PubMed ID: 33486890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
    Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
    JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Employment and absenteeism in working-age persons with multiple sclerosis.
    Salter A; Thomas N; Tyry T; Cutter G; Marrie RA
    J Med Econ; 2017 May; 20(5):493-502. PubMed ID: 28035846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.
    Abdelhak A; Antweiler K; Kowarik MC; Senel M; Havla J; Zettl UK; Kleiter I; Hoshi MM; Skripuletz T; Haarmann A; Stahmann A; Huss A; Gingele S; Krumbholz M; Selge C; Friede T; Ludolph AC; Overell J; Koendgen H; Clinch S; Wang Q; Ziemann U; Hauser SL; Kümpfel T; Green AJ; Tumani H
    Mult Scler Relat Disord; 2024 Jan; 81():105139. PubMed ID: 38000130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with Multiple Sclerosis.
    Maurino J; Martínez-Ginés ML; García-Domínguez JM; Solar MD; Carcelén-Gadea M; Ares-Luque A; Ballabriga J; Navarro-Cantó L; Medrano N; Honan CA;
    Mult Scler Relat Disord; 2020 Jun; 41():102046. PubMed ID: 32179482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of progression in primary progressive multiple sclerosis in a large Turkish cohort.
    Vural A; Derle E; Sayat-Gürel G; Karabudak R; Tuncer A
    Mult Scler Relat Disord; 2020 Feb; 38():101520. PubMed ID: 31743849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.
    Brown LJ; Li J; Brunner M; Snoke M; La HA
    J Med Econ; 2021; 24(1):140-149. PubMed ID: 33461357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory activity following motor progression due to critical CNS demyelinating lesions.
    Nayak S; Sechi E; Flanagan EP; Messina S; Kassa R; Kantarci O; Weinshenker BG; Keegan BM
    Mult Scler; 2021 Jun; 27(7):1037-1045. PubMed ID: 32812487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
    Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M
    Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment.
    Ouallet JC
    Rev Neurol (Paris); 2020 Jun; 176(6):500-504. PubMed ID: 32278541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
    Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
    Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
    Sayao AL; Bueno AM; Devonshire V; Tremlett H;
    Mult Scler; 2011 Nov; 17(11):1375-83. PubMed ID: 21677023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.
    Castelo-Branco A; Landfeldt E; Svedbom A; Löfroth E; Kavaliunas A; Hillert J
    Eur J Neurol; 2019 Apr; 26(4):603-609. PubMed ID: 30414299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability.
    Andersson PB; Waubant E; Gee L; Goodkin DE
    Arch Neurol; 1999 Sep; 56(9):1138-42. PubMed ID: 10488816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?
    Schwartz CE; Quaranto BR; Healy BC; Benedict RH; Vollmer TL
    Arch Phys Med Rehabil; 2013 Oct; 94(10):1971-81. PubMed ID: 23727344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.